



# Viral Epidemiology Snapshot: January 2-8, 2022

Prepared by Anne Hall, Ph.D., M(ASCP) on behalf of the Molecular Diagnostics/Virology Labs

## CoV-2, Flu, & RSV

Virus	#Tested	#Positive	% Positive
Flu A	804	22	2.7%
Flu B	804	2	0.2%
RSV	658	31	4.7%
CoV-2 PUI	3994	1363	34.1%
CoV-2 Surveillance	586	59	10.1%


## Other Respiratory Viruses

Virus	#Tested	#Positive	% Positive
Adenovirus	653	65	10.0%
Coronavirus 229E	652	4	0.6%
Coronavirus HKU1	652	0	0.0%
Coronavirus NL63	652	1	0.2%
Coronavirus OC43	652	32	4.9%
Metapneumovirus	652	126	19.3%
Rhinovirus/Enterovirus	652	100	15.3%
Parainfluenza 1	652	0	0.0%
Parainfluenza 2	652	2	0.3%
Parainfluenza 3	652	6	0.9%
Parainfluenza 4	652	5	0.8%

## Flu A Subtyping

2009 H1N1	0
Seasonal H1	0
Seasonal H3	14
No Subtype	7
Pending subtype	1

## Flu, RSV, & CoV-2 Trends




This report contains results for molecular and antigen tests ordered throughout the CHMCA network and performed at the Akron/Mahoning valley laboratories.

As of 11/14, this report also includes Point-of-Care tests (POCT) for influenza performed at ACHP locations.

Notes on Influenza A subtyping: Influenza A found by the Respiratory Film Array test will also include a subtype. Influenza A found by POCT methods will be listed as "no subtype".

## CoV-2 Positivity Rate Trends



Notes on SARS-CoV-2 data: In the top chart, the red CoV-2 line traces the total number of patients testing positive each week. In the bottom chart, the orange line ("PUI") shows data for all patients with symptoms or known exposures ("Patient Under Investigation") while the purple line ("Surv.") shows surveillance data for undergoing pre-procedure screening.

As of 10/31, the surveillance line shows patients who have been designated as "pre-procedure" in their testing order questionnaire, as well as participants in the employee screening program.

